Search Results

You are looking at 1 - 10 of 21 items for :

Clear All
Open access

Xu Han, Xuefeng Xu, Hongyun Ma, Yuan Ji, Dansong Wang, Tiantao Kuang, Wenchuan Wu, Bin Song, Gang Li, Gang Jin and Wenhui Lou

Journal of Surgical Pathology 2015 39 683 – 690 . ( https://doi.org/10.1097/PAS.0000000000000408 ) 10.1097/PAS.0000000000000408 12 Tang LH Basturk O Sue JJ Klimstra DS . A practical approach to the classification of WHO grade 3 (G3) Well

Open access

C E Higham, A Olsson-Brown, P Carroll, T Cooksley, J Larkin, P Lorigan, D Morganstein, P J Trainer and the Society for Endocrinology Clinical Committee

-threateningly unwell (CTCAE (Common Terminology Criteria for Adverse Events) grade 3–4: Algorithm 1 ). Algorithm 1 Management of a life-threateningly unwell (CTCAE grade 3–4) patient. Appropriate management of a mild-to-moderately unwell patient

Open access

Kosmas Daskalakis, Marina Tsoli, Anna Angelousi, Evanthia Kassi, Krystallenia I Alexandraki, Denise Kolomodi, Gregory Kaltsas and Anna Koumarianou

the entire cohort of 92 patients, 56 (61%) experienced any SE during first- or second-line MTT, mostly grades 1 and 2 toxicities. SEs grade >3 were encountered in 16 patients (17.4%). Table 5 summarizes the most common SE and the frequency of their

Open access

Martin Zweifel, Beat Thürlimann, Salome Riniker, Patrik Weder, Roger von Moos, Olivia Pagani, Martin Bigler, Karin M Rothgiesser, Christiane Pilop, Hanne Hawle, Peter Brauchli, Coya Tapia, Wolfgang Schoenfeld, Cristiana Sessa and for the Swiss Group for Clinical Cancer Research (SAKK)

another 3 confirmatory patients in the last dose cohort or in case of a dose-limiting toxicity (DLT). A DLT was defined as an adverse event (AE), laboratory abnormality or a drug toxicity ≥ grade 3 that was considered to be probably, possibly or definitely

Open access

Anne Jouinot, Bernard Royer, Etienne Chatelut, Sotheara Moeung, Guillaume Assié, Audrey Thomas-Schoemann, Jérôme Bertherat, François Goldwasser and Benoit Blanchet

progression-free survival (5 months) remain disappointing. Furthermore, lower rates of severe hematological toxicities are observed with EDP-mitotane regimen than with platinum-etoposide in small-cell lung cancer (SCLC) patients (11 vs 53% of grade 3

Open access

Sarah J Delforce, Eugenie R Lumbers, Celine Corbisier de Meaultsart, Yu Wang, Anthony Proietto, Geoffrey Otton, Jim Scurry, Nicole M Verrills, Rodney J Scott and Kirsty G Pringle

Grade 3 tumours. No exclusion criteria were used, as linked data were unavailable. Semi-quantitative real-time reverse transcriptase polymerase chain reaction (qPCR) Total RNA was isolated from FFPE tissues using the Qiagen RNeasy FFPE Kit

Open access

Ashley K Clift, Omar Faiz, Robert Goldin, John Martin, Harpreet Wasan, Marc-Olaf Liedke, Erik Schloericke, Anna Malczewska, Guido Rindi, Mark Kidd, Irvin M Modlin and Andrea Frilling

–Meier plot of patient survival stratified by WHO/ENETS tumour grade ( P  = 0.6). Grade 1 ( n  = 62), Grade 2 ( n  = 6) and Grade 3 ( n  = 2). Regarding ROC analysis for disease stage: for 5- and 10-year disease-specific survival, the corresponding

Open access

Ashley K Clift, Oskar Kornasiewicz, Panagiotis Drymousis, Omar Faiz, Harpreet S Wasan, James M Kinross, Thomas Cecil and Andrea Frilling

.e. grade 1 = <2%, grade 2 = 3–20%, and grade 3 = >20% ( 16 ). The TNM staging is a significant prognosticator, with 5-year overall survivals in stage I, II, III and IV disease being 100, 76, 22 and 14%, respectively, reported in a retrospective series of 57

Open access

R C S van Adrichem, L J Hofland, R A Feelders, M C De Martino, P M van Koetsveld, C H J van Eijck, R R de Krijger, D M Sprij-Mooij, J A M J L Janssen and W W de Herder

studies have shown a significant shorter survival in Grade 3 GEP NET patients (Ki-67 index >20%) (24, 25) . A possible explanation for our discrepant results could be the very small sample size of these heterogeneous tumor entities and the short follow

Open access

Anna Malczewska, Magdalena Witkowska, Karolina Makulik, Agnes Bocian, Agata Walter, Joanna Pilch-Kowalczyk, Wojciech Zajęcki, Lisa Bodei, Kjell Oberg and Beata Kos-Kudła

37 N/A  Functional 9 7 Grade  Grade 1 33 33 N/A  Grade 2 27 10  Grade 3 NET 2 1  Grade 3 NEC 3 –  No data 2 – TNM stage  Stage I 21 2 N/A  Stage IIA 8